

**Amendments to the Claims  
(Clean Version)**

✓ 4. Cancel

*Sub C1* 5. An immunogenic composition comprising,  
(a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of the heparin binding domain of fibroblast growth factor, and immunogenic fragments thereof; and  
(b) a pharmaceutically acceptable carrier.

*B2* 6. The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NOS: 1-or-2.

*Sub E1* 7. The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

*B3 E1* 11. The composition of Claim 5, further comprising a hydrophobic moiety attached to the immunogenic peptide.

✓ 14. Cancel

*E1 Sub C3* 15. An immunogenic composition comprising,  
(a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment corresponds to the receptor binding domain of vascular endothelial growth factor, and immunogenic fragments thereof; and  
(b) a pharmaceutically acceptable carrier.

*B4 C4* 16. The composition of Claim 15, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

*E 1*  
*B 4*  
*CMT*

17. The composition of Claim 15, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

*B 5*  
*E*

21. The composition of Claim 15, further comprising a hydrophobic moiety attached to the immunogenic peptide.

✓ 24. Cancel

*B 4*  
*Self*  
*C 4*  
thereof,

25. An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor,  
wherein the immunogenic peptide fragment of fibroblast growth factor consists of the heparin binding domain and immunogenic fragments  
and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of the receptor binding domain and immunogenic fragments thereof, and

(b) a pharmaceutically acceptable carrier.

**Amendments to the Claims  
(Marked Up Version)**

Please amend the following claims by deleting the words in brackets and inserting the underlined words.

4. (Cancel) An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of fibroblast growth factor; and
- (b) a pharmaceutically acceptable carrier.

5. (Once Amended) [The composition of Claim 4,] An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide [corresponds to] consists of the heparin binding domain of fibroblast growth factor, and immunogenic fragments thereof; and
- (b) a pharmaceutically acceptable carrier.

6. (Once Amended) The composition of Claim [4] 5, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NOS: 1 [and] or 2.

7. (Once Amended) The composition of Claim [4] 5, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

11. (Once Amended) The composition of Claim [4] 5, further comprising a hydrophobic moiety attached to the immunogenic peptide.

14. (Cancel) An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of vascular endothelial growth factor; and
- (b) a pharmaceutically acceptable carrier.

15. (Once Amended) [The composition of Claim 14,] An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of vascular endothelial growth factor  
wherein the immunogenic peptide fragment [corresponds to] consists of  
the receptor binding domain of vascular endothelial growth factor, and  
immunogenic fragments thereof; and  
(b) a pharmaceutically acceptable carrier.

16. (Once Amended) The composition of Claim [14] 15, wherein the amino acid sequence of the immunogenic peptide comprises [SEQ ID NOS: 3-9] SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

17. (Once Amended) The composition of Claim [14] 15, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

21. (Once Amended) The composition of Claim [14] 15, further comprising a hydrophobic moiety attached to the immunogenic peptide.

24. (Cancel) An immunogenic composition comprising,  
(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor; and  
(b) a pharmaceutically acceptable carrier.

25. (Once Amended) [The composition of Claim 24,] An immunogenic composition comprising,  
(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor,  
wherein the immunogenic peptide fragment of fibroblast growth factor  
[corresponds to] consists of the heparin binding domain [of fibroblast growth factor] and immunogenic fragments thereof,  
and wherein the immunogenic peptide fragment of vascular endothelial growth factor [corresponds to] consists of the receptor binding domain [of vascular endothelial growth factor] and immunogenic fragments thereof; and  
(b) a pharmaceutically acceptable carrier.

**Pending Claims**

*Following entry this amendment, Claims 5-13, 15-23, and 25-29 provided below will be pending in this application.*

5. An immunogenic composition comprising,
  - (a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of the heparin binding domain of fibroblast growth factor, and immunogenic fragments thereof; and
  - (b) a pharmaceutically acceptable carrier.
6. The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NOS: 1 or 2.
7. The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.
8. The composition of Claim 7, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.
9. The composition of Claim 7, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.
10. The composition of Claim 9, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed  $\beta$ -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

11. The composition of Claim 5, further comprising a hydrophobic moiety attached to the immunogenic peptide.

12. The composition of Claim 11, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

13. The composition of Claim 11, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

15. An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of the receptor binding domain of vascular endothelial growth factor, and immunogenic fragments thereof; and
- (b) a pharmaceutically acceptable carrier.

16. The composition of Claim 15, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

17. The composition of Claim 15, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

18. The composition of Claim 17, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

19. The composition of Claim 17, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

20. The composition of Claim 19, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed  $\beta$ -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

21. The composition of Claim 15, further comprising a hydrophobic moiety attached to the immunogenic peptide.

22. The composition of Claim 21, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

23. The composition of Claim 21, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

25. An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of the heparin binding domain and fragments thereof, and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of the receptor binding domain and immunogenic fragments thereof; and
- (b) a pharmaceutically acceptable carrier.

26. The composition of Claim 25, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

27. The composition of Claim 26, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

28. The composition of Claim 26, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

29. The composition of Claim 28, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed  $\beta$ -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.